New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

 

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Follow us on social media for the latest updates in B2B!

Image

Latest

Rothman Index
The Origin Story of the Rothman Index – Episode 5
January 8, 2026

Hospitals collect enormous amounts of clinical data, yet preventable patient decline remains a persistent challenge. Over the past two decades, hospitals have invested heavily in early warning scores and rapid response infrastructure, but translating data into timely, meaningful action has proven difficult. As clinicians contend with alert fatigue and increasing documentation burden, a more…

Read More
Rothman Index
My Mother and the Story of the Genesis of the Rothman Index – Episode 4
January 8, 2026

Healthcare generates enormous volumes of clinical data, yet making sense of that information in real time remains a challenge. Subtle changes in vitals, labs, and nursing assessments often precede serious events, but when that information is fragmented across the medical record, emerging risks can go unnoticed. The central challenge facing hospitals today is not…

Read More
home
Delivering Moments That Matter: The Art of Joy, Memory, and Meaning at Anthropologie Home
January 8, 2026

These days, ‘home’ means more than just four walls. It’s where people reset, gather, and express who they are—raising the bar for what they expect from the brands that help shape those spaces. Consumers are no longer just buying décor—they’re investing in meaning, memory, and moments that last. Research continues to show that people…

Read More
Texas energy
Small Margins, Big Risks: How Fraud Hurts Texas Energy Retailers
January 6, 2026

Fraud has quietly become one of the most existential threats in Texas’s deregulated retail electricity market—because the business runs on razor-thin margins and delayed payment. Under the non-POR system overseen by the Electric Reliability Council of Texas (ERCOT), retail energy providers assume the full risk of nonpayment. With profit margins often measured in just a…

Read More